HighGravityDataBioMarin Pharmaceutical — May 4, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-26-000006
Showing in the filing
Total Revenues (Full-Year)
“between $3.825 billion and $3.925 billion”
Period
FY2026
Measure
GAAP-tied
Source
Prose
All guidance in this release · 14
Total Revenues (Full-Year) for FY2026
“between $3.825 billion and $3.925 billion”
Total Revenues Growth Rate (Y/Y, at Midpoint) for FY2026
“20%”
PALYNZIQ Revenue for FY2026
“expected to increase year-over-year”
Amicus Acquisition Impact on Non-GAAP Dilute… for FY2026
“slightly dilutive”
Non-GAAP Diluted EPS Recognized in Second Ha… for H2 FY2026
“approximately two-thirds”
Total Revenues Expected in Second Half of 2026 for H2 FY2026
“more than 55%”
Non-GAAP Diluted EPS (Q2 vs Q1) for Q2 FY2026
“modestly higher than in Q1”
Total Revenues for FY2026
“$3,825 to $3,925”
Enzyme Therapies for FY2026
“$2,725 to $2,775”
VOXZOGO for FY2026
“$975 to $1,025”
Other Revenues for FY2026
“$100 to $125”
Non-GAAP Diluted EPS for FY2026
“$4.85 to $5.05”
Non-GAAP Diluted EPS - Weighted-Average Dilu… for FY2026
“approximately 200 million”
Non-GAAP Diluted EPS - combined company tax … for FY2026
“22%”
Exhibit 99.1 · the passage around this item
… earlier in the release
(415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2026 Financial and Operating Results First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint, and Reflecting the Addition of GALAFOLD ® and POMBILITI ® + OPFOLDA ® to BioMarin’s Portfolio Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., May 4, 2026 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the first quarter ended March 31, 2026. “With the acquisition of Amicus Therapeutics complete, the addition of GALAFOLD and POMBILITI + OPFOLDA to our commercial portfolio allows us to reach patients with Fabry and Pompe diseases and meaningfully strengthens and accelerates our near-to-mid-term growth rates,” said Alexander Hardy, President and Chief Executive Officer of BioMarin. “We expect these high-growth assets to support our strongest financial performance yet in 2026. Next quarter, we look forward to updating you on the longer‑term outlook of the Amicus integration based on our plans to leverage our global scale to expand the potential of these transformative therapies. With a faster-growing commercial portfolio, together with two near-term Phase 3 data readouts and ongoing pipeline progress expected over the coming quarters, we are well-positi
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.